Dapagliflozin/linagliptin - AJU Pharm
Alternative Names: AJU A51; Linagliptin/dapagliflozin - AJU PharmLatest Information Update: 28 Sep 2023
Price :
$50 *
At a glance
- Originator AJU Pharm
- Class Alkynes; Amines; Antihyperglycaemics; Benzhydryl compounds; Chlorobenzenes; Glucosides; Heart failure therapies; Ketones; Obesity therapies; Piperidines; Purines; Pyrans; Quinazolines; Small molecules; Urologics
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 09 Mar 2021 AJU Pharm completes a phase I trial in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT04972539)